Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The companies extended by four years a 2003 deal that granted IMCL a non-exclusive license to DYAX's antibody
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury